Sergi Papiol

Sergi Papiol

Auto-generated profile, based on publicly available information

Sergi Papiol

Max Planck Institute of Psychiatry

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Affective Disorders
Verified
Journal Article
Closed access
LPL. Plans
L. Plans
CBC. Barrot
C. Barrot
ENE. Nieto
E. Nieto
JRJosé Ríos
José Ríos
TST.G. Schulze
T.G. Schulze
ABA. Benabarre
A. Benabarre

5 April 2022 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
RBRachel M. Brouwer
Rachel M. Brouwer
MKMarieke Klein
Marieke Klein
KGKatrina Grasby
Katrina Grasby
HSHugo G. Schnack
Hugo G. Schnack
NJNeda Jahanshad
Neda Jahanshad
HPHilleke E. Hulshoff Pol
Hilleke E. Hulshoff Pol

16 March 2020 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
AAAzmeraw Amare
Azmeraw Amare
KSKlaus Oliver Schubert
Klaus Oliver Schubert
LHLiping Hou
Liping Hou
SCScott R. Clark
Scott R. Clark
SPSergi Papiol
Sergi Papiol
BBBernhard T Baune
Bernhard T Baune

29 November 2021 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
KSKlaus Oliver Schubert
Klaus Oliver Schubert
Anbupalam ThalamuthuAnbupalam Thalamuthu
Anbupalam Thalamuthu
AAAzmeraw Amare
Azmeraw Amare
JFJosef Frank
Josef Frank
FSFabian . Streit
Fabian . Streit
BBBernhard T Baune
Bernhard T Baune
Lithium is the gold standard therapy for Bipolar Disorder (BD) but its effectiveness differs widely between individuals. The molecular mechanisms underlying treatment response heterogeneity are not well understood, and personalized treatment in BD remains elusive. Genetic analyses of the lithium treatment response phenotype may generate novel molecular insights into lithium’s therapeutic mechanisms and lead to testable hypotheses to improve BD management and outcomes. We used fixed effect meta-analysis techniques to develop meta-analytic polygenic risk scores (MET-PRS) from combinations of highly correlated psychiatric traits, namely schizophrenia (SCZ), major depression (MD) and bipolar disorder (BD). We compared the effects of cross-disorder MET-PRS and single genetic trait PRS on lithium response. For the PRS analyses, we included clinical data on lithium treatment response and genetic information forn = 2283 BD cases from the International Consortium on Lithium Genetics (ConLi+Gen;www.ConLiGen.org). Higher SCZ and MD PRSs were associated with poorer lithium treatment response whereas BD-PRS had no association with treatment outcome. The combined MET2-PRS comprising of SCZ and MD variants (MET2-PRS) and a model using SCZ and MD-PRS sequentially improved response prediction, compared to single-disorder PRS or to a combined score using all three traits (MET3-PRS). Patients in the highest decile for MET2-PRS loading had 2.5 times higher odds of being classified as poor responders than patients with the lowest decile MET2-PRS scores. An exploratory functional pathway analysis of top MET2-PRS variants was conducted. Findings may inform the development of future testing strategies for personalized lithium prescribing in BD.

27 June 2017 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
SPS Papiol
S Papiol
DPD Popovic
D Popovic
DKDaniel Keeser
Daniel Keeser
AHA Hasan
A Hasan
TST Schneider-Axmann
T Schneider-Axmann
BMB Malchow
B Malchow
Preliminary studies suggest that, besides improving cognition, aerobic exercise might increase hippocampal volume in schizophrenia patients; however, results are not consistent. Individual mechanisms of volume changes are unknown but might be connected to the load of risk genes. Genome-wide association studies have uncovered the polygenic architecture of schizophrenia. The secondary analysis presented here aimed to determine the modulatory role of schizophrenia polygenic risk scores (PRSs) on volume changes in the total hippocampus and cornu ammonis (CA) 1, CA2/3, CA4/dentate gyrus (DG) and subiculum over time. We studied 20 multi-episode schizophrenia patients and 23 healthy controls who performed aerobic exercise (endurance training) combined with cognitive remediation for 3 months and 21 multi-episode schizophrenia patients allocated to a control intervention (table soccer) combined with cognitive remediation. Magnetic resonance imaging-based assessments were performed at baseline and after 3 months with FreeSurfer. No effects of PRSs were found on total hippocampal volume change. Subfield analyses showed that the volume changes between baseline and 3 months in the left CA4/DG were significantly influenced by PRSs in schizophrenia patients performing aerobic exercise. A larger genetic risk burden was associated with a less pronounced volume increase or a decrease in volume over the course of the exercise intervention. Results of exploratory enrichment analyses reinforced the notion of genetic risk factors modulating biological processes tightly related to synaptic ion channel activity, calcium signaling, glutamate signaling and regulation of cell morphogenesis. We hypothesize that a high polygenic risk may negatively influence neuroplasticity in CA4/DG during aerobic exercise in schizophrenia.

11 July 2023 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
AAAzmeraw Amare
Azmeraw Amare
ATAnbupalam Thalamuthu
Anbupalam Thalamuthu
KSKlaus Oliver Schubert
Klaus Oliver Schubert
JFJanice Fullerton
Janice Fullerton
MAMuktar Ahmed
Muktar Ahmed
BBBernhard T. Baune
Bernhard T. Baune
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li+PGS) in patients with BD. To gain further insights into lithium’s possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li+PGS was developed in the International Consortium of Lithium Genetics cohort (ConLi+Gen: N = 2367) and replicated in the combined PsyCourse (N = 89) and BipoLife (N = 102) studies. The associations of Li+PGS and lithium treatment response — defined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at P < 0.05. Li+PGS was positively associated with lithium treatment response in the ConLi+Gen cohort, in both the categorical (P = 9.8 × 10−12, R2 = 1.9%) and continuous (P = 6.4 × 10−9, R2 = 2.6%) outcomes. Compared to bipolar patients in the 1st decile of the risk distribution, individuals in the 10th decile had 3.47-fold (95%CI: 2.22–5.47) higher odds of responding favorably to lithium. The results were replicated in the independent cohorts for the categorical treatment outcome (P = 3.9 × 10−4, R2 = 0.9%), but not for the continuous outcome (P = 0.13). Gene-based analyses revealed 36 candidate genes that are enriched in biological pathways controlled by glutamate and acetylcholine. Li+PGS may be useful in the development of pharmacogenomic testing strategies by enabling a classification of bipolar patients according to their response to treatment.